Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

danaher corp. - DHR

DHR

Close Chg Chg %
228.59 -1.46 -0.64%

Closed Market

227.14

-1.46 (0.64%)

Volume: 4.09M

Last Updated:

Dec 4, 2025, 3:59 PM EDT

Trade Now

Company Overview: danaher corp. - DHR

DHR Key Data

Open

$228.00

 Day Range

223.77 - 228.88

52 Week Range

171.01 - 258.23

 Market Cap

$161.37B

Shares Outstanding

706.35M

 Public Float

643.48M

Beta

0.89

 Rev. Per Employee

N/A

P/E Ratio

46.63

 EPS

$4.89

Yield

54.28%

 Dividend

$0.32

EX-DIVIDEND DATE

Sep 26, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

3.65M

  

DHR Performance

1 Week
 
 0.74%
 
1 Month
 
 8.82%
 
3 Months
 
 14.11%
 
1 Year
 
 -0.72%
 
5 Years
 
 15.31%
 

DHR Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 28
Full Ratings ➔

About danaher corp. - DHR

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, and Diagnostics. The Biotechnology segment includes bioprocessing, discovery, and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

DHR At a Glance

Danaher Corp.
2200 Pennsylvania Avenue North West
Washington, District of Columbia 20037-1701
Phone 1-202-828-0850 Revenue 23.88B
Industry Medical Specialties Net Income 3.90B
Sector Health Technology Employees 63,000
Fiscal Year-end 12 / 2025
View SEC Filings

DHR Valuation

P/E Current 46.634
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 43.402
Price to Sales Ratio 7.088
Price to Book Ratio 3.332
Price to Cash Flow Ratio 25.30
Enterprise Value to EBITDA 24.456
Enterprise Value to Sales 7.719
Total Debt to Enterprise Value 0.093

DHR Efficiency

Revenue/Employee 378,968.254
Income Per Employee 61,888.889
Receivables Turnover 5.438
Total Asset Turnover 0.295

DHR Liquidity

Current Ratio 1.397
Quick Ratio 1.054
Cash Ratio 0.306

DHR Profitability

Gross Margin 59.502
Operating Margin 21.713
Pretax Margin 19.46
Net Margin 16.331
Return on Assets 4.813
Return on Equity 7.569
Return on Total Capital 5.847
Return on Invested Capital 5.685

DHR Capital Structure

Total Debt to Total Equity 34.608
Total Debt to Total Capital 25.71
Total Debt to Total Assets 22.112
Long-Term Debt to Equity 33.24
Long-Term Debt to Total Capital 24.694
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Danaher Corp. - DHR

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
29.45B 31.47B 23.89B 23.88B
Sales Growth
+32.17% +6.85% -24.09% -0.06%
Cost of Goods Sold (COGS) incl D&A
11.50B 12.52B 9.86B 9.67B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.17B 2.22B 2.17B 2.35B
Depreciation
718.00M 738.00M 675.00M 721.00M
Amortization of Intangibles
1.45B 1.48B 1.49B 1.63B
COGS Growth
+17.25% +8.88% -21.29% -1.90%
Gross Income
17.95B 18.95B 14.03B 14.21B
Gross Income Growth
+43.90% +5.55% -25.94% +1.23%
Gross Profit Margin
+60.95% +60.21% +58.74% +59.50%
2021 2022 2023 2024 5-year trend
SG&A Expense
9.90B 10.25B 8.76B 9.02B
Research & Development
1.74B 1.75B 1.50B 1.58B
Other SG&A
8.16B 8.51B 7.25B 7.44B
SGA Growth
+21.30% +3.53% -14.60% +3.05%
Other Operating Expense
- - - -
-
Unusual Expense
400.00M 403.00M 348.00M 534.00M
EBIT after Unusual Expense
7.65B 8.29B 4.93B 4.65B
Non Operating Income/Expense
189.00M 212.00M 402.00M 274.00M
Non-Operating Interest Income
11.00M 41.00M 303.00M 117.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
241.00M 214.00M 289.00M 278.00M
Interest Expense Growth
-11.72% -11.20% +35.05% -3.81%
Gross Interest Expense
241.00M 214.00M 289.00M 278.00M
Interest Capitalized
- - - -
-
Pretax Income
7.60B 8.29B 5.04B 4.65B
Pretax Income Growth
+69.03% +9.13% -39.17% -7.89%
Pretax Margin
+25.80% +26.35% +21.11% +19.46%
Income Tax
1.25B 1.08B 823.00M 747.00M
Income Tax - Current - Domestic
346.00M 413.00M 756.00M 301.00M
Income Tax - Current - Foreign
1.13B 1.23B 1.27B 929.00M
Income Tax - Deferred - Domestic
(206.00M) (400.00M) (866.00M) (342.00M)
Income Tax - Deferred - Foreign
(23.00M) (159.00M) (338.00M) (141.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
6.35B 7.21B 4.22B 3.90B
Minority Interest Expense
- - - -
-
Net Income
6.35B 7.21B 4.22B 3.90B
Net Income Growth
+74.08% +13.58% -41.45% -7.63%
Net Margin Growth
+21.55% +22.91% +17.67% +16.33%
Extraordinaries & Discontinued Operations
- - 86.00M 543.00M
-
Discontinued Operations
- - 86.00M 543.00M
-
Net Income After Extraordinaries
6.43B 7.21B 4.76B 3.90B
Preferred Dividends
- 164.00M 106.00M 21.00M
Net Income Available to Common
6.27B 7.10B 4.74B 3.90B
EPS (Basic)
8.7727 9.7959 6.4399 5.3338
EPS (Basic) Growth
+76.50% +11.66% -34.26% -17.18%
Basic Shares Outstanding
714.60M 725.10M 736.50M 731.00M
EPS (Diluted)
8.6143 9.6636 6.3827 5.2889
EPS (Diluted) Growth
+76.33% +12.18% -33.95% -17.14%
Diluted Shares Outstanding
736.80M 737.10M 743.10M 737.20M
EBITDA
10.22B 10.92B 7.45B 7.54B
EBITDA Growth
+67.87% +6.86% -31.82% +1.22%
EBITDA Margin
+34.69% +34.70% +31.16% +31.56%

Snapshot

Average Recommendation BUY Average Target Price 254.20
Number of Ratings 28 Current Quarters Estimate 2.138
FY Report Date 12 / 2025 Current Year's Estimate 7.714
Last Quarter’s Earnings 1.89 Median PE on CY Estimate N/A
Year Ago Earnings 7.48 Next Fiscal Year Estimate 8.411
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 21 17 24 24
Mean Estimate 2.14 2.00 7.71 8.41
High Estimates 2.23 2.10 7.80 8.70
Low Estimate 2.10 1.85 7.67 8.30
Coefficient of Variance 1.15 2.97 0.40 1.19

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 20 19 20
OVERWEIGHT 4 4 5
HOLD 4 4 2
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Danaher Corp. - DHR

Date Name Shares Transaction Value
Nov 20, 2025 Jonathan B. Leiken SVP- General Counsel 26,767 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 20, 2025 Jonathan B. Leiken SVP- General Counsel 10,172 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 20, 2025 Julie Sawyer Montgomery Executive Vice President 16,653 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $221.21 per share 3,683,810.13
Nov 20, 2025 Robert Bradley Gray SVP Strategic Development 11,614 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $221.21 per share 2,569,132.94
Nov 20, 2025 Greg Milosevich Executive Vice President 4,420 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $221.21 per share 977,748.20
Jul 29, 2025 Alan G. Spoon Director 30,172 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 29, 2025 Linda Hefner Filler Director 8,890 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 29, 2025 Feroz Dewan Director 1,706 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 29, 2025 Elias A. Zerhouni Director 17,809 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 29, 2025 A. Shane Sanders Director 2,350 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 29, 2025 Teri L. List-Stoll Director 7,621 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 29, 2025 Raymond C. Stevens Director 6,728 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Alan G. Spoon Director 1,478 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Raymond C. Stevens Director 1,478 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Teri L. List-Stoll Director 1,478 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Elias A. Zerhouni Director 1,478 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Feroz Dewan Director 1,478 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 John T. Schwieters Director 1,478 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 John T. Schwieters Director 17,096 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Linda Hefner Filler Director 1,478 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Danaher Corp. in the News